Time is of the essence in balancing risks and benefits
Drug UPDATES
Information on New Approvals and Medication Safety
Drug Updates
Information on New Approvals and Medication Safety
Drug Updates
Information on New Approvals and Medication Safety
Tips for E-Prescribing
This year marks the second year of CMS’ electronic prescribing incentive program for office-based physicians.
Colcrys Approval Triggers Questions
Some rheumatologists question the depth of research and the approval’s implications for patient access
Drug Updates
Information on New Approvals and Medication Safety
Letters to the Editor: In Memoriam
One more prescribing rule [See “Rheuminations,” September 2009, p. 6], honored mainly in the breach, in our overspending climate: don’t prescribe an expensive brand when generics are as good or better, especially Nexium (which I have never prescribed) versus omeprazole, Lipitor versus simvastatin (which now costs the VA three cents a pill), and—for rheumatologists who are writing 80% Uloric—allopurinol except for the 10% who might need Uloric.
Pharmaceutical Tourism
Could trade agreements and not bulky legislation be the key to cheaper drugs?
Letters
Feedback From Our Readers
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- Next Page »